Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 59-63

  Galetta, D ^a   Gebbia, V ^b   Silvestris, N ^a   Ferrau F ^c   Carrozza, F ^d   Cigolari, S ^e   Russo, P ^b   Calista, F ^f   Adamo, V ^g   Colucci, G ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b LA MADDALENA CANCER CENTER   (Italy)

^c Taormina Hospital   (Italy)

^d Cardarelli Hospital   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

Author keywords

Advanced non small cell lung cancer; Brain metastases; Chemotherapy; Cisplatin; Fotemustine; Radiotherapy

Indexed keywords

CISPLATIN; FOTEMUSTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CREATININE BLOOD LEVEL; DAILY LIFE ACTIVITY; DIARRHEA; DRUG PENETRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PIASTRINOPENIA; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; TREATMENT OUTCOME;

EID: 79952186245     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.013     Document Type: Article

References (27)

1. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
2. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
3. Lagerwaard F., Levendag P., Nowak P., Eijkenboom W., Hanssens P., Schmitz P. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795-803.
4. Tsao M.N., Lloyd N., Wong R., Chow E., Rakovitch E., Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006, 3:CD003869.
5. Bradley K.A., Mehta Management of brain metastases. Semin Oncol 2004, 31:693-701.
6. Doolittle N.D., Abrey L.E., Bleyer W.A., Brem S., Davis T.P., Dore-Duffy P., et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting. Clin Cancer Res 2005, 11:421-428.
7. Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007, 25:2306-2312.
8. Pujol J.L., Monnier A., Berille J., Cerrina M.L., Douillard J.Y., Rivière A., et al. Phase II study of nitrosurea fotemustine as single drug chemotherapy in poor prognosis non small cell lung cancer. Br J Cancer 1994, 69:1136-1140.
9. Rivière A., Le Cesne A., Berille J., Baio S., Le Chevalier T. Cisplatin fotemustine combination in inoperable non small cell lung cancer: preliminary report of a French multicenter phase II trial. Eur J Cancer 1994, 30A:587-590.
10. Cotto C., Berille J., Souquet P.J., Riou R., Croisile B., Turjman F., et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non small cell lung cancer. Eur J Cancer 1996, 32A:69-71.
11. Robinet G., Thomas P., Breton J.L., Léna H., Gouva S., Dabouis G., et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francaise de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001, 12:59-67.
12. Lee D.H., Han J.Y., Kim H.T., Yoon S.J., Pyo H.R., Cho K.H., et al. Primary chemotherapy for newly diagnosed non small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 2008, 113:143-149.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Shah S., Vanclay F., Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989, 42:703-709.
15. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
16. Langer C., Metha M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005, 23:6207-6219.
17. Wong J., Hird A., Kirou-Mauro A., Napolskikh J., Chow E. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 2008, 15:25-45.
18. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., McKenna W.G., Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
19. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529-2536.
20. Antonadou D., Paraskevaidis M., Sarris G., Coliarakis N., Economou I., Karageorgis P., et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20:3644-3650.
21. Suh J.H., Stea B., Nabid A., Kresl J.J., Fortin A., Mercier J.P., et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006, 24:106-114.
22. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
23. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized tral comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
24. Bernardo G., Cuzzoni Q., Strada M.R., Bernardo A., Brunetti G., Jedrychowska I., et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 2002, 20:293-302.
25. Avril M.F., Aamdal S., Grob J.J., Hauschild A., Mohr P., Bonerandi J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
26. Cortot A.B., Gerinière L., Robinet G., Breton J.L., Corre R., Falchero L., et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006, 17:1412-1417.
27. Olson J.J., Paleologos N.A., Gaspar L.E., Robinson P.D., Morris R.E., Ammirati M., et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010, 96:115-142.